{"organizations": [], "uuid": "37fb110051d9d5d1271f62e2ba4718288275a554", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/23/pr-newswire-qiagen-receives-fda-clearance-for-first-ever-jak2-test-for-use-in-diagnosis-of-additional-myeloproliferative-neoplasms.html", "country": "US", "domain_rank": 767, "title": "QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.216, "site_type": "news", "published": "2018-01-24T00:05:00.000+02:00", "replies_count": 0, "uuid": "37fb110051d9d5d1271f62e2ba4718288275a554"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/23/pr-newswire-qiagen-receives-fda-clearance-for-first-ever-jak2-test-for-use-in-diagnosis-of-additional-myeloproliferative-neoplasms.html", "ord_in_thread": 0, "title": "QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms", "locations": [], "entities": {"persons": [{"name": "john gilardi", "sentiment": "none"}, {"name": "thomas theuringer", "sentiment": "none"}], "locations": [{"name": "germantown", "sentiment": "none"}, {"name": "maryland", "sentiment": "none"}, {"name": "germany", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "qiagen", "sentiment": "negative"}, {"name": "qiagen n.v.", "sentiment": "none"}, {"name": "qia", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "HILDEN, Germany, and GERMANTOWN, Maryland, January 23, 2018 /PRNewswire/ --\nQIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.\nClick here for the ful l press release\nhttps://corporate.qiagen.com/newsroom/press-releases/2017/20180119_ipsogen_jak2?sc_lang=en\nContacts:\nQIAGEN\nInvestor Relations\nJohn Gilardi\ne-mail: ir@QIAGEN.com\n+49-2103-29-11711\nPublic Relations\nDr. Thomas Theuringer\ne-mail: pr@QIAGEN.com\n+49-2103-29-11826\nSOURCE Qiagen N.V.", "external_links": ["https://corporate.qiagen.com/newsroom/press-releases/2017/20180119_ipsogen_jak2?sc_lang=en"], "published": "2018-01-24T00:05:00.000+02:00", "crawled": "2018-01-24T00:39:21.053+02:00", "highlightTitle": ""}